{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:42Z","timestamp":1790610822429,"version":"4.1.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020261","name":"Meharry Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270763"],"award-info":[{"award-number":["82270763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82325009"],"award-info":[{"award-number":["82325009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kint.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:38:35Z","timestamp":1779259115000},"page":"337-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti\u2013glomerular basement membrane disease: variant forms and underlying mechanisms"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-291X","authenticated-orcid":false,"given":"Huang","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-xia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-279X","authenticated-orcid":false,"given":"Dorin-Bogdan","family":"Borza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.03.029_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrneph.2011.89","article-title":"Advances in human antiglomerular basement membrane disease","volume":"7","author":"Cui","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"4S","key":"10.1016\/j.kint.2026.03.029_bib2","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103531","article-title":"Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: a systematic review and meta-analysis","volume":"23","author":"Kuang","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2026.03.029_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1084\/jem.126.6.989","article-title":"The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis","volume":"126","author":"Lerner","year":"1967","journal-title":"J Exp Med"},{"key":"10.1016\/j.kint.2026.03.029_bib5","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1074\/jbc.274.16.11267","article-title":"The goodpasture autoantigen: mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain","volume":"274","author":"Netzer","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.03.029_bib6","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1074\/jbc.275.8.6030","article-title":"The goodpasture autoantigen: identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain","volume":"275","author":"Borza","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.03.029_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa0910500","article-title":"Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis","volume":"363","author":"Pedchenko","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.029_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.04.001","article-title":"Antibodies to \u03b15 chain of collagen IV are pathogenic in Goodpasture's disease","volume":"70","author":"Cui","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.kint.2026.03.029_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102885","article-title":"ANCA and anti-glomerular basement membrane double-positive patients: a systematic review of the literature","volume":"20","author":"Philip","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2026.03.029_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ajkd.2005.05.003","article-title":"Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis","volume":"46","author":"Rutgers","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2016.02.001","article-title":"The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis","volume":"89","author":"Nasr","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib13","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3389\/fimmu.2020.02035","article-title":"Clinical-pathological features and outcome of atypical anti-glomerular basement membrane disease in a large single cohort","volume":"11","author":"Shen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2023.11.003","article-title":"Atypical anti-glomerular basement membrane nephritis: a case series from the French Nephropathology Group","volume":"83","author":"Chauveau","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/jclinpath-2018-205278","article-title":"Clinicopathological features and outcome of antibody-negative anti-glomerular basement membrane disease","volume":"72","author":"Liang","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.kint.2026.03.029_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib143","unstructured":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE). ClinicalTrials.gov Identifier: NCT02994927. Updated March 24, 2025. Accessed May 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02994927"},{"key":"10.1016\/j.kint.2026.03.029_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.029_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10875-012-9772-2","article-title":"Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease","volume":"33","author":"Ma","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib19","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.ekir.2021.07.001","article-title":"Eculizumab and complement activation in anti-glomerular basement membrane disease","volume":"6","author":"Nithagon","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib20","article-title":"Case report: eculizumab and ECMO rescue therapy of severe ARDS in Goodpasture syndrome","volume":"8","author":"Sobotta","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2026.03.029_bib21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2023.05.017","article-title":"Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13730-024-00929-4","article-title":"Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report","volume":"14","author":"Tanaka","year":"2025","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib23","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib24","first-page":"691","article-title":"Possible implication of intermolecular epitope spreading in the production of anti-glomerular basement membrane antibody in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"40","author":"Nishibata","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.kint.2026.03.029_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2215\/CJN.05270515","article-title":"Autoantibodies against linear epitopes of myeloperoxidase in anti-glomerular basement membrane disease","volume":"11","author":"Li","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib26","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1681\/ASN.2018090946","article-title":"Peroxidasin-a novel autoantigen in anti-GBM disease?","volume":"29","author":"McAdoo","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib27","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1681\/ASN.2018050519","article-title":"Inhibitory anti-peroxidasin antibodies in pulmonary-renal syndromes","volume":"29","author":"McCall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJM197406132902403","article-title":"Evolution of membranous nephropathy into anti-glomerular-basement-membrane glomerulonephritis","volume":"290","author":"Klassen","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.029_bib29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/ki.2013.364","article-title":"The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy","volume":"85","author":"Jia","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.ajkd.2020.11.023","article-title":"Concurrent anti-glomerular basement membrane antibody disease and membranous nephropathy: a case series","volume":"78","author":"Ahmad","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib31","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1080\/0886022X.2022.2141645","article-title":"Clinical and pathological features of anti-glomerular basement membrane disease associated with membranous nephropathy: an observational study","volume":"44","author":"Zhang","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib32","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.ekir.2023.07.031","article-title":"The characteristics of concurrent anti-glomerular basement membrane nephritis and membranous nephropathy","volume":"8","author":"Bu","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0272-6386(03)00664-4","article-title":"A dual pattern of immunofluorescence positivity","volume":"42","author":"Nasr","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib34","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1681\/ASN.2010090923","article-title":"Membranous nephropathy with crescents","volume":"22","author":"Basford","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000523713","article-title":"Predictors of kidney outcomes of anti-glomerular basement membrane disease in a large Chinese cohort","volume":"53","author":"Jia","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib36","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.ekir.2022.07.006","article-title":"Concurrent PLA2R-associated membranous nephropathy and antiglomerular basement membrane disease","volume":"7","author":"Jagannathan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ekir.2020.01.010","article-title":"Membranous nephropathy with crescents","volume":"5","author":"Alawieh","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib38","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.ekir.2019.07.021","article-title":"Membranous glomerulonephritis with crescents","volume":"4","author":"Nikolopoulou","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12882-024-03637-4","article-title":"Diagnosis of membranous nephropathy with anti-GBM glomerulonephritis: a case series report","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000520641","article-title":"Anti-phospholipase A2 receptor in nonlupus patients with membranous nephropathy and crescents","volume":"2","author":"Zuo","year":"2022","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1681\/ASN.2022050581","article-title":"Risk stratification to predict renal survival in anti-glomerular basement membrane disease","volume":"34","author":"Floyd","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2023.12.011","article-title":"Evaluation of the risk prediction models in predicting kidney outcomes in antiglomerular basement membrane disease","volume":"9","author":"Kuang","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41581-018-0057-8","article-title":"HLA and kidney disease: from associations to mechanisms","volume":"14","author":"Robson","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib46","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.kint.2022.11.021","article-title":"Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy","volume":"103","author":"Zhang","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature22329","article-title":"Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells","volume":"545","author":"Ooi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.kint.2026.03.029_bib48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12882-023-03132-2","article-title":"Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report","volume":"24","author":"Cheng","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.03.029_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000505738","article-title":"Membranous nephropathy due to anti-GBM antibodies of mice and men","volume":"51","author":"Glassock","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000505443","article-title":"Epitope mapping of human \u03b13(IV)NC1-induced membranous nephropathy in mice","volume":"51","author":"Wang","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib52","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/jcmm.13134","article-title":"The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif","volume":"21","author":"Hu","year":"2017","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.kint.2026.03.029_bib53","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.4049\/jimmunol.1401267","article-title":"Glomerulopathy induced by immunization with a peptide derived from the goodpasture antigen \u03b13IV-NC1","volume":"194","author":"Hopfer","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib54","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.4049\/jimmunol.1103368","article-title":"Murine membranous nephropathy: immunization with \u03b13(IV) collagen fragment induces subepithelial immune complexes and Fc\u03b3R-independent nephrotic syndrome","volume":"188","author":"Zhang","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib55","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1681\/ASN.2008101086","article-title":"Cellular origins of type IV collagen networks in developing glomeruli","volume":"20","author":"Abrahamson","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajim.4700210204","article-title":"The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome)","volume":"21","author":"Bombassei","year":"1992","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.kint.2026.03.029_bib57","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0090-1229(87)90109-7","article-title":"Studies on the formation of glomerular immune deposits in brown Norway rats injected with mercuric chloride","volume":"45","author":"Fukatsu","year":"1987","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.kint.2026.03.029_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2023.07.011","article-title":"An unusual case of anti-glomerular basement membrane disease and phospholipase A(2) receptor-associated membranous nephropathy after exposure to hydrocarbons","volume":"83","author":"Eley","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.03.029_bib62","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ckj\/sfad068","article-title":"Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy","volume":"16","author":"Shen","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.029_bib63","article-title":"Spectrum of biopsy proven renal diseases in central China: a 10-year retrospective study based on 34,630 cases","volume":"10","author":"Hu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib64","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1053\/ajkd.2002.32799","article-title":"Goodpasture syndrome during the course of a Schonlein-Henoch purpura","volume":"39","author":"Carreras","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib65","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pathol.2018.09.065","article-title":"Concurrent anti-GBM disease and IgA glomerulonephritis","volume":"51","author":"Longano","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.kint.2026.03.029_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2267138","article-title":"Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study","volume":"45","author":"Hu","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2323160","article-title":"Coexistence of anti-glomerular basement membrane disease and IgA nephropathy: an illustrative case and comprehensive literature review","volume":"46","author":"Chen","year":"2024","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib69","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/nep.13040","article-title":"Fever and prodromal infections in anti-glomerular basement membrane disease","volume":"23","author":"Gu","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2026.03.029_bib70","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1523-1755.2004.00486.x","article-title":"Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy","volume":"65","author":"Xie","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib71","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1681\/ASN.2019060619","article-title":"Experimental antiglomerular basement membrane GN induced by a peptide from actinomyces","volume":"31","author":"Gu","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib72","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.5884","article-title":"Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model","volume":"257","author":"Wan","year":"2022","journal-title":"J Pathol"},{"key":"10.1016\/j.kint.2026.03.029_bib73","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.03.029_bib74","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.ekir.2025.04.016","article-title":"Carboxymethyl-lysine is a prominent target of circulating IgA in IgA nephropathy","volume":"10","author":"Alibrandi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib75","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1681\/ASN.V1191656","article-title":"Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease","volume":"11","author":"Tanji","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/08860220500461195","article-title":"Concurrent antiglomerular basement membrane disease and immune complex glomerulonephritis","volume":"28","author":"Cui","year":"2006","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib77","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.ekir.2023.08.029","article-title":"The prevalence and characteristics of circulating IgA anti-glomerular basement membrane autoantibodies in anti-glomerular basement membrane disease","volume":"8","author":"Yang","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14179","article-title":"Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease","volume":"35","author":"Singh","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib79","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ekir.2021.04.011","article-title":"Recurrence and outcome of anti-glomerular basement membrane glomerulonephritis after kidney transplantation","volume":"6","author":"Coche","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib80","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1016\/j.ekir.2025.06.021","article-title":"Outcomes after kidney transplantation in anti-GBM disease","volume":"10","author":"Traversat","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/IJNRD.S150539","article-title":"Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation","volume":"11","author":"Kashtan","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib82","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ekir.2018.01.008","article-title":"Genotype and outcome after kidney transplantation in Alport syndrome","volume":"3","author":"Gillion","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib83","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/ajkd.2002.31997","article-title":"Renal transplant in patients with Alport's syndrome","volume":"39","author":"Byrne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib84","first-page":"1983","article-title":"Identification of post-transplant anti-alpha 5 (IV) collagen alloantibodies in X-linked Alport syndrome","volume":"11","author":"Dehan","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib85","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.1998.00794.x","article-title":"Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation","volume":"53","author":"Brainwood","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib86","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1159\/000101791","article-title":"Autoepitopes and alloepitopes of type IV collagen: role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis","volume":"106","author":"Borza","year":"2007","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib87","doi-asserted-by":"crossref","first-page":"10670","DOI":"10.1074\/jbc.M611892200","article-title":"The alloantigenic sites of alpha3alpha4alpha5(IV) collagen: pathogenic X-linked Alport alloantibodies target two accessible conformational epitopes in the alpha5NC1 domain","volume":"282","author":"Kang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.03.029_bib88","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ki.1995.170","article-title":"A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome","volume":"47","author":"Kalluri","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib89","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1681\/ASN.2005060670","article-title":"Distinct epitopes for anti-glomerular basement membrane Alport alloantibodies and Goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib90","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.transproceed.2011.11.035","article-title":"Outcome of renal transplantation in Alport's syndrome: a single-center experience","volume":"44","author":"Gumber","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2026.03.029_bib91","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ekir.2023.03.010","article-title":"Atypical anti-glomerular basement membrane disease","volume":"8","author":"Bharati","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib92","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2024.02.011","article-title":"\"Atypical\" anti-GBM disease: just atypical, or not anti-GBM disease at all?","volume":"84","author":"Ivkovi\u0107","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib93","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2024.01.515","article-title":"Anti-glomerular basement membrane disease: broadening the spectrum","volume":"83","author":"Cornell","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/ckj\/sfw068","article-title":"Atypical anti-glomerular basement membrane disease: lessons learned","volume":"9","author":"Glassock","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.029_bib95","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2016.01.018","article-title":"Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical","volume":"89","author":"Rosales","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib96","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.ajkd.2022.07.006","article-title":"Autoimmunity in anti-glomerular basement membrane disease: a review of mechanisms and prospects for immunotherapy","volume":"81","author":"Kuang","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ndt\/gfaf153","article-title":"Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease","volume":"41","author":"Kuang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib98","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2016.05.015","article-title":"Outcomes of patients with Goodpasture syndrome: a nationwide cohort-based study from the French Society of Hemapheresis","volume":"73","author":"Huart","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.kint.2026.03.029_bib99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/ijn.IJN_414_19","article-title":"Recurrent, atypical anti-glomerular basement membrane disease","volume":"31","author":"Jamboti","year":"2021","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-240543","article-title":"Relapse of treated anti-GBM disease following hair dye use","volume":"14","author":"Povey","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib101","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(96)90169-9","article-title":"Recurrent Goodpasture's disease","volume":"27","author":"Levy","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5414\/CNP67240","article-title":"Patient with antibody-negative relapse of Goodpasture syndrome","volume":"67","author":"Benz","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ckj\/sfw038","article-title":"Multiple recurrences of anti-glomerular basement membrane disease with variable antibody detection: can the laboratory be trusted?","volume":"9","author":"Liu","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.029_bib104","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12882-018-1197-6","article-title":"Recurrence of Goodpasture syndrome without circulating anti-glomerular basement membrane antibodies after kidney transplant, a case report","volume":"20","author":"Thibaud","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2502607","article-title":"Clinical and pathological features of patients with recurrent anti-glomerular basement membrane disease","volume":"47","author":"Liu","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib106","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2004.09.029","article-title":"Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1\/alpha2 chains of type IV collagen","volume":"45","author":"Borza","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib107","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ckj\/sfw048","article-title":"Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical phenotype and antibody characteristics over time","volume":"9","author":"Gu","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.029_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2975131","article-title":"Antibody-negative relapse of Goodpasture syndrome with pulmonary hemorrhage","volume":"2019","author":"Rohm","year":"2019","journal-title":"Case Rep Med"},{"key":"10.1016\/j.kint.2026.03.029_bib109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ndt\/5.2.87","article-title":"Distribution of Goodpasture antigens within various human basement membranes","volume":"5","author":"Weber","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib110","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1681\/ASN.2020101431","article-title":"Laminin-521 is a novel target of autoantibodies associated with lung hemorrhage in anti-GBM disease","volume":"32","author":"Shen","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib111","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2023.07.023","article-title":"Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease","volume":"104","author":"Kuang","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib112","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/bmj.292.6516.301","article-title":"Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4","volume":"292","author":"Savage","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.kint.2026.03.029_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217990","article-title":"Atypical presentation of anti-GBM nephritis in a 90-year-old patient","volume":"2016","author":"Okiro","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib114","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1053\/j.ajkd.2010.09.022","article-title":"Clinical features and outcomes of anti-glomerular basement membrane disease in older patients","volume":"57","author":"Cui","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.029_bib115","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1080\/0886022X.2022.2147673","article-title":"Clinicopathological characteristics and outcome predictors of anti-glomerular basement membrane glomerulonephritis","volume":"44","author":"Ge","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib116","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study","volume":"33","author":"Uhlin","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib144","unstructured":"A Study With Imlifidase in Anti-GBM Disease (GOOD-IDES-02). ClinicalTrials.gov Identifier: NCT05679401. Updated March 4, 2026. Accessed May 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05679401"},{"key":"10.1016\/j.kint.2026.03.029_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.1973.14","article-title":"Anti-glomerular basement membrane antibody-induced glomerulonephritis","volume":"3","author":"Wilson","year":"1973","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib118","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ki.1978.72","article-title":"Goodpasture's syndrome: an analysis of 29 cases","volume":"13","author":"Teague","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib119","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1081\/JDI-120013957","article-title":"Outcomes in patients with Goodpasture's syndrome and hydrocarbon exposure: review","volume":"24","author":"Shah","year":"2002","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.03.029_bib121","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ndt\/13.4.935","article-title":"Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function","volume":"13","author":"Ang","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib122","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/sj.ki.5002525","article-title":"Antiglomerular basement membrane disease with normal renal function","volume":"72","author":"Cui","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib123","article-title":"The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.03.029_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-14-19","article-title":"The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease","volume":"14","author":"Qu","year":"2013","journal-title":"BMC Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.humimm.2009.04.004","article-title":"The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity","volume":"70","author":"Zhao","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib126","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.ki.5000135","article-title":"Natural autoantibodies against glomerular basement membrane exist in normal human sera","volume":"69","author":"Cui","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib127","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/ki.2009.348","article-title":"Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity","volume":"76","author":"Zhao","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib128","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.4049\/jimmunol.1202204","article-title":"Proteolysis breaks tolerance toward intact \u03b1345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for \u03b1345NC1 hexamers","volume":"190","author":"Olaru","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.03.029_bib129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/0886022X.2020.1869042","article-title":"The clinical and immunological features of the post-extracorporeal shock wave lithotripsy anti-glomerular basement membrane disease","volume":"43","author":"Wang","year":"2021","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.03.029_bib130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.akdh.2024.04.007","article-title":"Anti-glomerular basement membrane disease: recent updates","volume":"31","author":"Bharati","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.kint.2026.03.029_bib131","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.kint.2026.03.029_bib132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/imm.12736","article-title":"The susceptible HLA class II alleles and their presenting epitope(s) in Goodpasture's disease","volume":"151","author":"Xie","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.kint.2026.03.029_bib133","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib134","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.029_bib135","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.03.029_bib136","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.0000000000000159","article-title":"Stimulation of immune checkpoint molecule B and T-lymphocyte attenuator alleviates experimental crescentic glomerulonephritis","volume":"34","author":"Diefenhardt","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.029_bib137","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI6710","article-title":"CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis","volume":"105","author":"Reynolds","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.03.029_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103521","article-title":"Clinical phenotype of AAV, anti-GBM disease and double-positive patients after SARS-CoV-2 vaccination","volume":"23","author":"Li","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2026.03.029_bib139","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.kint.2021.09.002","article-title":"COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?","volume":"100","author":"Li","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib140","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.kint.2020.06.009","article-title":"Anti-glomerular basement membrane disease during the COVID-19 pandemic","volume":"98","author":"Prendecki","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.029_bib141","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ckj\/sfab204","article-title":"Incidence of anti-glomerular basement membrane disease during the COVID-19 pandemic","volume":"15","author":"Prema","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.029_bib142","first-page":"161","article-title":"A mini-epidemic of Goodpasture's syndrome clinical and immunological studies","volume":"13","author":"Perez","year":"1974","journal-title":"Nephron"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:20:21Z","timestamp":1785885621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826003923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0085253826003923"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.029","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013glomerular basement membrane disease: variant forms and underlying mechanisms","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}